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TO THE EDITOR
I was glad to read the recent online
publication of the NEJM article by
Zhang et al. (2013) from the Institute
of Dermatology, Shangdong Provin-
cial Academy of Medical Sciences,
China. From this paper, we noted that
our findings published in the Journal
of Investigative Dermatology were
proved further (Wang et al., 2013). It
is interesting to note that we inde-
pendently applied different research
approaches for the same scientific
problem and achieved similar con-
clusions.
Six years ago, when I was appointed
the Director of the National Center
for Leprosy Control and Prevention of
China CDC, I had the opportunity to go
to leprosaria in China and found several
cases of dapsone-induced hypersensitiv-
ity reaction (DIHR), a special type of
severe drug eruption. From 2009 to
2010, Dr Jianping Shen, a clinical expert
of leprosy in our center, performed an
epidemiological survey of the mortality
factors of leprosy patients in China and
found that DIHR ranked as the second
highest cause of death (Shen et al.,
2011; Tian et al., 2012). I asked Dr
Hongsheng Wang, a professor of
dermatology and the head of the
leprosy laboratory of our center, to
select a few DIHR cases for a pilot
study of HLA typing in early 2011. A
few weeks later, he told me that all the
four cases that he had examined were
HLA-B*1301 positive. Therefore, we
decided to collect all cases of drug-
induced hypersensitivity syndrome
(DIHS) reported to our center through
LepMis (http://218.2.99.162/) and
completed this case-control study. In
all, we examined 21 cases of DIHR in
leprosy patients (see Supplementary
Table S1 online) and performed MHC I
region typing and genetic polymorph-
isms of related metabolism enzymes,
and we discovered that genetic
susceptibility to DIHR is carried on the
HLA-B*1301 haplotype, without influ-
ence from the genotypes or phenotypes
of the important dapsone metabolism
enzymes NAT2 and CYP 2C9 (Wang
et al., 2013). We performed this study
on the basis of the following conside-
rations: first, DIHR is categorized under
the DIHS or the drug rash with eosino-
philia and systemic symptoms syndro-
mes (Kardaun et al., 2007; Kumari et al.,
2011); second, numerous reports have
described the associations between
human leukocyte antigens (HLAs,
especially MHC I) and drug eruptions
in patients with various diseases, and
that these HLA profiles are useful tools
in diagnosing and, moreover, in preven-
ting life-threatening adverse drug
reactions (Chung et al., 2004; Mallal
et al., 2008; Pavlos et al., 2012); and
third, previous studies have proved that
genetic polymorphism of human drug
metabolism enzymes is a predisposing
factor for allergic diseases, lupus erythe-
matosus, Stevens–Johnson syndrome,
and toxic epidermal necrolysis
(Zielinska et al., 1997; Gawronska-
Szklarz et al., 1999; Von Schmiedeberg
et al., 1999; Wolkenstein et al., 2005).
Zhang’s team performed a genome-
wide association study on 77 DIHR
patients and on 2,064 controls and
discovered that the presence of
HLA-B*1301 could predict the risk of
DIHR with a sensitivity and specificity
of above 85% (Zhang et al., 2013).
Those individuals who carry a single
copy of HLA-B*1301 run a 34-fold
higher risk of being hit by DIHR as
compared with those who do not carry
this allele, and the risk is magnified 100-
fold for those who carry two copies of
HLA-B*1301.
I declare on behalf of the authorship
group that we were not aware whether
an overlap of study populations existed
at the time of submission or publication
of our paper, even though Dr Shen had
shared patient information with Dr
Zhang Furen. After our communication
following the recent publication of our
letter, Dr Zhang informed me that our
four cases of DIHR (cases 7, 10, 12,
and 15, Supplementary Table S1) over-
lapped with his. All four cases were
revealed to be HLA-B*1301 positive by
our two teams.
I am delighted that two different
teams in China have found indepen-
dently the association between
HLA-B*1301 and DIHR among leprosy
patients in China. I believe that our
two teams in China will collaborate in
verifying the value of HLA-B*1301 as a
predictive biomarker for DIHR in a
large-scale prospective study.
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TO THE EDITOR
Chronic mucocutaneous candidiasis dis-
ease (CMCD), first described clinically
in 1969, is characterized by recurrent
or persistent infections of the skin
and mucosae with Candida albicans
with no or a few other clinical manifes-
tations (Kirkpatrick, 2001; Lilic, 2002).
In 2011, Puel et al. (2011) identified the
first inborn errors of IL-17 immunity
underlying CMCD: complete auto-
somal-recessive IL-17RA and partial
autosomal-dominant (AD) IL-17F
deficiencies. AD CMCD has since
been shown to be caused by hetero-
zygous mutations in the coiled-coil
domain of the STAT1 gene (Liu et al.,
2011; Smeekens et al., 2011; van de
Veerdonk et al., 2011; Hori et al.,
2012; Takezaki et al., 2012; Toth
et al., 2012; Solte´sz et al., 2013;
Wang et al., 2013) and accounts for
the majority of cases. All of these
mutations are gain of function (GOF)
and were shown to induce an increa-
sed STAT1 phosphorylation in res-
ponse to IFN-ab, IFN-g and IL-27
due to an impaired nuclear STAT1
dephosphorylation, resulting in a gain
of transcriptional activity (Liu et al.,
2011; Takezaki et al., 2012). More-
over, CMCD patients with STAT1 GOF
mutations showed a highly reduced
number of IL-17-producing CD4þT
cells, as assessed both ex vivo and
after in vitro differentiation of T cells
(Liu et al., 2011; Smeekens et al., 2011;
van de Veerdonk et al., 2011; Takezaki
et al., 2012).
An 8-year-old Tunisian girl, born to
first-cousin parents, was admitted be-
cause of the progressive appearance
of facial scaly plaques that evolved for
2 years. She had a history of an episode
of vulvovaginal candidiasis at the age of
7 years, which was successfully treated.
Examination revealed keratosic erythe-
matous plaques on the cheekbones and
nose, multiple crusted papules on the
upper and lower limbs, a rifle thrush,
a perleche, and a squamo-columnar
crusty cheilitis. The direct mycological
examination showed many filaments
and yeast colonies. The skin biopsy of
facial lesions showed a polymor-
phic inflammatory infiltrate made up of
granulomas and with the presence of
multiple filaments and spores. A stan-
dard staging found multiple candidiasis
lesions of the nose, ear, and esophagus.
The patient recovered after 6 months
of oral treatment with fluconazole.
Because of the disseminated chronic
mucocutaneous candidiasis and the
absence of HIV or immunosuppression,
CMCD was suspected and further inves-
tigations were performed, ruling out a
diagnosis of autoimmune polyendocrine
syndrome or other immunodeficiencies.
The patient is now 13 years old. A
recurrence of candidiasis was observed
but was controlled by anti-fungal treat-
ment. She did not suffer from any other
severe infections, auto-immune mani-
festations, or cerebral aneurysms. She
was the only affected individual in her
family and no familial history was
reported.
Written consent was obtained before
investigation and adherence to the
Declaration of Helsinki Principles was
maintained. The patient’s genomic DNA
sequencing of the STAT1 coiled-coilAccepted article preview online 11 November 2013; published online 12 December 2013
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